Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Pico Rivera, California Clinical Trials

A listing of Pico Rivera, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (726) clinical trials

Clinical Trial Evaluating ITI-007 as a Monotherapy for the Treatment of Bipolar Depression

The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

Phase

0.0 miles

Learn More »

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

Phase

0.0 miles

Learn More »

A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)

This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.

Phase

0.62 miles

Learn More »

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201. No statistical hypothesis tests will be performed.

Phase

0.62 miles

Learn More »

Participatory Research to Advance Colon Cancer Prevention

The study will fulfill the following aims: Aim 1: Develop personalized messages (e.g., phone scripts, text messages, patient portal prompts) and define an intervention using boot camp translation to increase colon cancer screening among Latino populations. Aim 2: Assess the reach, effectiveness, and differences by subgroup (e.g., preferred language) of ...

Phase N/A

0.62 miles

Learn More »

Evaluate TV-46000 as Maintenance Treatment in Adult Patients With Schizophrenia

The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously as compared to placebo during maintenance treatment in adult patients with schizophrenia. The study will include male and female patients, 18 to 65 years of age, who have a ...

Phase

0.62 miles

Learn More »

A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication

Participants will receive oral doses of ASP4345 or matching placebo QD (once daily) for 12 weeks. All participants will be administered the first dose of blinded study drug at the site following randomization and provided with web-based applications that provide supplemental cognitive training and record treatment compliance. Participants will return ...

Phase

0.62 miles

Learn More »

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

The objective of the study is to investigate the efficacy, safety and pharmacokinetics of four different doses of BI 425809 once daily compared to placebo given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment.

Phase

0.62 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB). The secondary objectives of this study are to evaluate the safety and tolerability of BIIB104 in participants with CIAS, and to ...

Phase

0.62 miles

Learn More »

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of ABT-494 Dose A once daily (QD) and Dose B QD versus placebo in participants with moderately to severely active Psoriatic Arthritis (PsA) who have an inadequate response ...

Phase

1.81 miles

Learn More »